SCYX - SCYNEXIS Inc Market Cap to Sales Volume

Corporate company logo of SCYNEXIS, Inc. (SCYX)

SCYNEXIS, Inc. (SCYX) develops innovative antimycotics, leveraging its partnership with GSK and expansion within hospitals. On GURU.Markets, the price-to-sales ratio exhibits volatility, with the latest value recorded as 1.80. While stock options help retain a strong scientific team, the high burn rate and dependence on R&D trials create significant financial risks for the business.

SCYNEXIS, Inc. (SCYX): Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for SCYNEXIS, Inc. (SCYX)

- market price and analyst price targets:
Stock Quotes scynexis.com|SCYX - Consensus Target
- market capitalization statistics:
Market Value Scynexis|SCYX - Enterprise Value
- book capitalization information:
Net Assets per Share SCYNEXIS|SCYX - Company Book Value|Market-to-Book Ratio scynexis.com|SCYX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio SCYNEXIS, Inc.|SCYX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient scynexis.com|SCYX - Company Debts|Debts to Net Assets Scynexis|SCYX - Company Long-Term Debts|Company Current Liabilities SCYNEXIS|Immediate Liquidity scynexis.com
- net income and valuation ratios data:
SCYX - Company Net Income|Net Profit Forecast SCYNEXIS, Inc.|SCYX - P/E Multiple|Projected Price to Earnings Ratio scynexis.com|SCYX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Scynexis|SCYX - Operating profit EBITDA|Net earnings per share for the last four quarters SCYNEXIS|SCYX - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months scynexis.com|SCYX - Net earnings per share growth this year|Expected earnings per share trend next year SCYNEXIS, Inc.
- total revenue and sales volume data:
SCYX - Revenue and Sales Volume|Company Future Sales scynexis.com|SCYX - Price-to-Revenue Ratio|Market Cap to Projected Revenue Scynexis
Fundamental company analysis:SCYX, SCYNEXIS Inc
Manufactured products of SCYNEXIS Inc

The P/S ratio determines the market value of a business relative to its annual revenue, measuring the premium investors are willing to pay per unit of sales. The P/S ratio dynamics for SCYNEXIS, Inc. (SCYX) reflect the impact of the global antifungal distribution partnership on the company's capitalization. The expansion of clinical indications for its drugs directly scales cash flow, adjusting the fundamental valuation of the asset. A stable trend for this indicator minimizes the risk of overpaying for future growth.

Competing companies

Market Cap to Revenue summittxinc.com SMMT|Moderna - Market Cap to Revenue|Market Cap to Sales Volume PCVX (Vaxcyte Inc)|Tarsus Pharma - P/S Multiple|Price-to-Revenue Coefficient CorMedix Therapeutics CRMD|Seres Therapeutics (MCRB) - Price-to-Revenue Ratio|Price to Sales sperotherapeutics.com (SPRO)|Price-to-Revenue Ratio AN2 Therapeutics Inc|Market Cap to Revenue Ratio PYPD (PolyPid Limited)|Price-to-Revenue Ratio YS Biopharma (LSB)|Price-to-Revenue Coefficient iterumtx.com|Price-to-Revenue Ratio BiomX PHGE|Price-to-Revenue Coefficient Soligenix Inc (SNGX)|60 Degrees Pharma - P/S Multiple|oragenics.com (OGEN) - Market Cap to Revenue|OPGN (OpGen Corp) - Market Cap to Revenue